Legend Biotech USA Inc

3 clinical trials · Sponsor

Record	Firm	Date
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer (NCT05680922)	Legend Biotech USA Inc	2023-07-26
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma (NCT05539430)	Legend Biotech USA Inc	2023-04-18
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (NCT04712864)	Legend Biotech USA Inc	2021-09-13

Every clearance here is in the API, with alerts when new ones post.